Primary Series Hospitalization/Severe Disease ■ non-mRNA ■ Multiple mRNA Study Country Design VE (95% CI) С \blacksquare 0.95 (0.92, 0.97) Bar-On et al., 2021 Israel Barda et al., 2021 Israel MC \vdash 0.93 (0.88, 0.97) С Muhsen et al., 2022 0.93 (0.85, 0.97) Israel ---USA MCSharma et al., 2021 0.45 (0.27, 0.58) Mattiuzzi and Lippi, 2022 С 0.69 (0.56, 0.78) Italy USA С 0.82 (0.56, 0.94) McConeghy et al., 2022 (S1) С USA McConeghy et al., 2022 (S2) 0.46 (-0.16, 0.79)Mehta et al., 2022 USA MC 0.81 (0.80, 0.82) С USA 0.70 (0.48, 0.83) Tartof et al., 2022 MC Butt et al, 2022 USA 0.52 (0.46, 0.57) UK Hulme et al., 2022 MC 0.80 (0.78, 0.82) Andersson et al., 2022 **Finland** MC **---**0.96 (0.88, 1.00) 0.88 (0.71, 1.00) Andersson et al., 2022 MC Norway MC 0.90 (0.80, 1.00) Andersson et al., 2022 Sweden Andersson et al., 2022 Sweden MC 0.88 (0.81, 0.95) USA MC \vdash loannou et al., 2022 0.53 (0.48, 0.58) Ng et al., 2022 С Singapore 0.70 (0.49, 0.82) Kislaya et al., 2022 (60-79yo) Portugal С 0.21 (0.02, 0.36) С Kislaya et al., 2022 (80+yo) Portugal 0.16 (0.01, 0.28) Ridgway et al., 2022 USA **MCC** \vdash 0.59 (0.54, 0.63) Desai et al., 2022 USA MC 0.44 (0.02, 0.68) 0.80 (0.56, 0.91) Chemaitelly et al., 2022 Qatar MC -0.250 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)

Mortality

